Actinium Pharmaceuticals, Inc.

AMEX:ATNM

Biotechnology

Healthcare
$1.64 +15.94%

+$0.22 today

Market cap
$51.56M
Beta
0.02
P/E (TTM)
4.4
EPS (TTM)
$0.36
52W Low $0.74High $1.74

Volume 0.18M

Average 0.15M

ATNM Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Actinium Pharmaceuticals, Inc.AMEX: ATNM

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation declines year over year

Q2 FY2026 stock-based compensation of $118K fell 40.1% year over year, ahead of the -98.0% change in trailing-twelve-month stock-based compensation. Over 3 fiscal years it compounded at +48.7% a year.

Context

  • Stock-based compensation amounted to 10211.1% of revenue in FY2025.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -40.1% holds above the trailing-twelve-month pace of -98.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$118K— QoQ
Last fiscal yearDec 2025
$9.19M+73.7% YoY
LTMJun 2026
$237K-98.0% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-40.1%——
1 year+73.7%——
3-year CAGR+48.7%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
9.19M USD
Year-over-year change
+73.7%
4-year CAGR
+52.6%

Stock-Based Compensation vs competitors

How ATNM compares with its peers on the latest reported figures

  • ATNM's LTM Jun 2026 stock-based compensation of $237K is the smallest of the 5 companies compared; the peer median is $3.99M.
  • Its year-over-year change of -98.0% is the 4th highest of 5, against a peer median of -28.5%.
  • Stock-based compensation amounts to 0.7% of revenue for ATNM, versus a peer median of 12.1%.
ATNM Competitors Peer median
Stock-Based Compensation for ATNM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PDSBPDS Biotechnology CorporationLTM Mar 2026$1.79B -27809.6%+824.6%—
OKUROnKure Therapeutics, Inc.LTM Mar 2026$11.67M +86.0%+523.5%—
XLOXilio Therapeutics, Inc.LTM Mar 2026$6.49M +5.8%-6.3%12.1%
ANVSAnnovis Bio, Inc.LTM Mar 2026$1.48M -62.7%+481.3%—
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$237K -98.0%+48.7%0.7%
Peer median (excluding ATNM) $3.99M-28.5%+502.4%12.1%

Competitors are the stored peer set for ATNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(24.77M)(33.02M)(48.82M)(38.24M)(33.89M)
Depreciation & Amortization524K699K790K811K821K
Deferred Income Tax(1.55M)402K000
Stock-Based Compensation1.69M2.8M3.84M5.29M9.19M
Change in Working Capital1.69M38.17M(3.15M)(932K)(704K)
Accounts Receivables00000
Inventory00000
Accounts Payables1.2M4.6M(2.18M)(387K)(346K)
Other Working Capital495K33.57M(972K)(545K)(358K)
Other Non-Cash Items1.55M(402K)000
Operating Cash Flow(20.87M)8.64M(47.34M)(33.07M)(24.58M)
Capital Expenditures(133K)(366K)(153K)(11K)(104K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(133K)(366K)(153K)(11K)(104K)
Debt Repayment(85K)(49K)(4K)(9K)(10K)
Common Stock Issued35.3M23.16M14.87M29.26M0
Common Stock Repurchased0000(207K)
Dividends Paid00000
Other Financing Activities6K0075K0
Financing Cash Flow35.22M23.11M14.87M29.32M(217K)
Effect of Forex Changes00(11K)06K
Net Change in Cash14.22M31.39M(32.63M)(3.76M)(24.9M)
Free Cash Flow(21M)8.28M(47.49M)(33.08M)(24.68M)

Actinium Pharmaceuticals, Inc.

AMEX:ATNM

Intrinsic Alpha fair value

Locked

Current Price

$1.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.